CD47 and glioblastoma: Collectively, the data from the fully immunocompetent model treated with oHSV expressing the murine version of anti-CD47 antibody backs up our data of oHSV expressing an anti-human CD47 antibody, suggesting that an oHSV expressing a full-length antibody with a strong Fc-dependent effect can effectively treat GBM with a local administration.